Marshall Wace
RARE icon

Marshall Wace’s Ultragenyx Pharmaceutical RARE Stock Holding History

Marshall Wace’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.34M Buy
159,889
+2,363
+2% +$58.7K ﹤0.01% 1341
2026
Q1 		$3.3M Buy
157,526
+85,358
+118% +$1.92M ﹤0.01% 1521
2025
Q4 		$1.66M Sell
72,168
-73,926
-51% -$2.43M ﹤0.01% 1666
2025
Q3 		$4.39M Buy
146,094
+80,223
+122% +$2.41M ﹤0.01% 1239
2025
Q2 		$2.4M Sell
65,871
-268,207
-80% -$9.67M ﹤0.01% 1474
2025
Q1 		$12.1M Sell
334,078
-717,495
-68% -$29.8M 0.02% 702
2024
Q4 		$44.2M Buy
1,051,573
+229,561
+28% +$11.4M 0.05% 311
2024
Q3 		$45.7M Sell
822,012
-311,088
-27% -$15.8M 0.06% 303
2024
Q2 		$46.6M Buy
1,133,100
+164,110
+17% +$7.01M 0.06% 278
2024
Q1 		$45.2M Sell
968,990
-520,496
-35% -$24.6M 0.07% 280
2023
Q4 		$71.2M Buy
1,489,486
+548,723
+58% +$21.3M 0.12% 168
2023
Q3 		$33.5M Buy
940,763
+14,126
+2% +$560K 0.07% 295
2023
Q2 		$42.7M Buy
926,637
+21,112
+2% +$979K 0.08% 260
2023
Q1 		$36.3M Buy
905,525
+570,100
+170% +$24.5M 0.08% 288
2022
Q4 		$15.5M Buy
335,425
+254,711
+316% +$10M 0.04% 574
2022
Q3 		$3.34M Sell
80,714
-270,936
-77% -$13.9M 0.01% 1676
2022
Q2 		$21M Sell
351,650
-33,803
-9% -$2.08M 0.04% 446
2022
Q1 		$28M Buy
385,453
+151,223
+65% +$10.5M 0.05% 384
2021
Q4 		$19.7M Buy
234,230
+204,288
+682% +$16.6M 0.04% 495
2021
Q3 		$2.7M Sell
29,942
-5,587
-16% -$505K 0.01% 1335
2021
Q2 		$3.39M Buy
+35,529
New +$3.7M 0.02% 1071
2021
Q1 		– Sell
-26,014
Closed -$3.6M – 2793
2020
Q4 		$3.6M Buy
+26,014
New +$3.09M 0.02% 697
2016
Q1 		– Sell
-29,656
Closed -$3.33M – 1167
2015
Q4 		$3.33M Sell
29,656
-44,337
-60% -$4.43M 0.03% 469
2015
Q3 		$7.13M Buy
73,993
+14,044
+23% +$1.61M 0.09% 231
2015
Q2 		$6.14M Sell
59,949
-62,664
-51% -$4.87M 0.08% 265
2015
Q1 		$7.61M Buy
+122,613
New +$6.81M 0.1% 242

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Marshall Wace's RARE Position: Q2 2026 in Review

Marshall Wace increased its Ultragenyx Pharmaceutical (RARE) stake by 1.5% in Q2 2026, buying an estimated $58.7K and bringing the position to 159,889 shares worth $5.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1341.

Marshall Wace first reported a position in RARE in Q1 2015 and has held it in 26 quarters since. The position peaked at $71.2M in Q4 2023. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Marshall Wace held 159,889 shares of Ultragenyx Pharmaceutical worth $5.34M as of Q2 2026.
  • Marshall Wace bought 2,363 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $58.7K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1341 holding.
  • Marshall Wace first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 26 quarters since.
  • Marshall Wace's Ultragenyx Pharmaceutical position peaked at $71.2M in Q4 2023.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.